arginyl-glycyl-aspartic acid has been researched along with Coronary Thrombosis in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dai, S; Jia, Q; Jiang, J; Lv, L; Wang, J; Wang, S; Wang, Y | 1 |
| Polokoff, MH; Shebuski, RJ; Sitko, GR; Stabilito, IJ | 1 |
2 other study(ies) available for arginyl-glycyl-aspartic acid and Coronary Thrombosis
| Article | Year |
|---|---|
rLj-RGD3, a novel recombinant toxin protein from Lampetra japonica, prevents coronary thrombosis-induced acute myocardial infarction by inhibiting platelet functions in rats.
Topics: Adenosine Diphosphate; Animals; beta-Thromboglobulin; Blood Platelets; Calcium; Coronary Thrombosis; Cyclic AMP; Electrocardiography; Heart Ventricles; Lampreys; Male; Myocardial Infarction; Myocardium; Oligopeptides; Platelet Adhesiveness; Platelet Aggregation; Rats, Sprague-Dawley; Recombinant Proteins; Serotonin | 2018 |
Acceleration of recombinant tissue-type plasminogen activator-induced thrombolysis and prevention of reocclusion by the combination of heparin and the Arg-Gly-Asp-containing peptide bitistatin in a canine model of coronary thrombosis.
Topics: Animals; Coronary Circulation; Coronary Disease; Coronary Thrombosis; Dogs; Drug Combinations; Electric Stimulation; Female; Fibrinolytic Agents; Hemodynamics; Heparin; Male; Myocardial Reperfusion; Partial Thromboplastin Time; Peptides; Platelet Aggregation; Recombinant Proteins; Recurrence; Snake Venoms; Tissue Plasminogen Activator | 1990 |